WO1991018615A1 - Human peripheral blood cells in an immunocompromised host - Google Patents
Human peripheral blood cells in an immunocompromised host Download PDFInfo
- Publication number
- WO1991018615A1 WO1991018615A1 PCT/US1991/003306 US9103306W WO9118615A1 WO 1991018615 A1 WO1991018615 A1 WO 1991018615A1 US 9103306 W US9103306 W US 9103306W WO 9118615 A1 WO9118615 A1 WO 9118615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- host
- human
- bone marrow
- cells
- murine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
Definitions
- the field of this invention is the production of human hematopoietic cells.
- the blood cell system comprising the diverse cells emanating from a single stem cell is essential to the survival and well being of mammals.
- the cells serve to carry oxygen, cleanse the body of debris, inhibit the proliferation of pathogens, monitor for neoplastic cells, and provide a wide variety of factors essential for their own and the growth of other cells.
- chimeric mice were developed, where human fetal tissue was introduced into CB-17 scid/scid mice to provide the chimeric SCID-hu mouse. The mice were shown to maintain for extended periods of time, human fetal lymph node and thymus and provide for peripheral blood cells, when supplied with a source of hematopoietic stem cells from fetal liver.
- peripheral blood cells it would be desirable to have a relatively high proportion of the peripheral blood cells as human cells' and desirably have a significant proportion of the total number of hematopoietic cells being human cells. Further, it would be desirable to have circulatory myelomonocytic cells and red blood cells, besides lymphoid cells.
- Xenogeneic bone marrow is introduced into an endogenous bone marrow depleted genetically immunocompromised mammalian host, where the bone marrow may be present as bone tissue or dispersed bone marrow, particularly from a fetal source.
- the fetal bone tissue may be conveniently introduced into the peritoneal cavity or the bone marrow may be injected into the long bone of the immunocompromised host.
- Non-human mammals particularly small mammals under 25kg, are provided having human peripheral blood cells present as at least two percent (2%) of the total peripheral blood cells, preferably at least five percent (5%) of the total peripheral blood cells and more preferably at least about fifteen percent (15%) .
- the enhanced level of human cells may be achieved by depletion of endogenous bone marrow, particularly stem cells, conveniently by irradiating the host with at least a sublethal dosage of radiation, generally being at least about 200 rad and varying with the size and nature of the host.
- the blood cells are then reconstituted with human bone marrow, conveniently as human bone or bone marrow cell suspensions, particularly from a fetal source.
- the human bone marrow source may be introduced before and after ablation to enhance the survival rate of the host upon ablation, particularly by irradiation.
- Various immunocompromised hosts may be employed, where the host being immunocompromised is as a result of a natural mutation, breeding, transformation of embryonic cells to provide a transgenic mouse, or the like.
- hosts which lack a functional lymphoid lineage The lack of the immune system may be as a result of a lack of a particular organ, a genetic defect, such as an incompetent reco binase or regulatory gene regulating the expression of the recombinase, transport of slg and T cell receptors to the surface, non-functional major histocompatibility antigens, or the like.
- CB-17 scid/scid mice and mice derived therefrom which may have further enhanced immunodeficiency, e.g. lack of natural killer (NK) cells.
- the host is irradiated or treated in any convenient manner to substantially ablate the endogenous bone marrow.
- X-irradiation may be employed where the level of radiation will be selected to provide at least substantially complete ablation of the hematopoietic cell system, while maintaining a reasonable, preferably a high, proportion of viable hosts. With each type of host, the particular level of irradiation may be selected by screening for the level of remaining viable hematopoietic cells for the efficiency of the ablation.
- Other techniques for bone marrow ablation which may be employed by themselves or in combination include cytotoxic drugs, immunotoxins, antibodies to lymphokines and growth factors, antibodies to natural killer cells, etc. The selection of cytotoxic drugs would be based on their ability to clear quickly from the lymphatic and blood circulatory systems, so as to rapidly be reduced to a non-cytotoxic level, prior to or shortly after the administration of the human bone marrow.
- the human bone marrow will normally be fetal bone marrow and may be employed as bone marrow slices, fragments, chunks, or the like, coming from various parts of the fetus, such as the femur, tibia, humerus or rib.
- the longest dimensions of human bone will generally be in the size range of about 8mm to 2cm, where the bone may be fragmented along the long axis, usually in not more than about four parts.
- the total volume of fetal bone which is introduced into the host will vary with the size of the host. For mice, the volume will generally be in the range of about 40mm 3 to 1,200mm 3 .
- human fetal bone marrow cell suspensions may be injected into long bones, such as the femur or tibia.
- long bones such as the femur or tibia.
- the volume of the bone marrow suspension will be in the range of about 10ml to 50ml for a mouse.
- the age of the host will generally be at least neonatal and usually not more than about six months, more usually not more than three months.
- the particular age is not critical to this invention, but younger animals are more convenient to handle and are more economical.
- the site of introduction of the fetal bone portions may be interperitoneal, subcutaneous, mammary fat pad, or other convenient site.
- the host After introduction of the bone marrow, the host is grown in accordance with conventional ways, feeding the host as appropriate, either with or without the presence of antibiotics in the feed. Conveniently, about 0.2% to 1.2% of sulfamethoxazole/trimethoprim (Septra) may be provided in the feed. As appropriate, additional introductions of the human fetal bone marrow may be made, usually not more than about two additional explants, generally at four to twenty week intervals.
- the host may receive a variety of growth factors and cytokines, either native to the host or human. Interleukins, colony stimulating factors, hormones, or the like may be added, such as IL-1, IL-3, IL-6, and G-CSF. Generally, the amount of the additive will vary, depending upon the particular additive, the host, and the like. For example, in the case of IL-3 0.5 - 5 ⁇ g/day may be administered. In the subject host, it is found that the bone tissue shows variable cellularity from 10 to 80%.
- the human cells comprise a significant proportion of the blood cells in circulation in the peripheral blood. The cells may include members of the lymphoid, myelomonocytic and erythroid lineages.
- the cells may be detected by employing a wide variety of antibodies which are commercially available for the detection of human markers on blood cells, such as CD-3, -A , -8, -10, -13, -15, -19, -20, -33, -41, -45, -59, HLA, or the like.
- a blood sample may be taken and assayed employing a fluorescence activated cell sorter.
- the cells may be lysed and a Western blot employed.
- Other techniques which may find use for the quantitative determination of a particular cell type include the polymerase chain reaction, gel electrophoresis, HPLC, or the like.
- lymph node In addition to the bone marrow, other human organs may also be present, particularly thy us, lymph node, skin, liver, pancreas, tonsil, appendix, epithelium, kidney, etc.
- One or more mesenteric or peripheral lymph nodes may be introduced.
- the various organs may be introduced conveniently in the kidney capsule, mammary fat pad, particularly the fourth mammary fat pad for a mouse, the popliteal fossa, or other convenient site where the organ may be vascularized, lymphatic vessels connected and maintained by the host for a reasonable period of time, usually at least four weeks, preferably at least six weeks.
- the non-human mammal may provide for a significant portion of the human hematopoietic system with the continued regeneration of stem cells and generation of more than fifty percent (50%) of the different types of committed or mature cells.
- cells of the myelomonocytic lineage such as macrophages, mast cells, neutrophils (PMNs) , eosinophils, basophils, monocytes, megakaryocytes, etc. or the lymphoid lineage, B lymphocytes, T lymphocytes, NK cells, ADCC cells, LAK cells, TIL cells, etc. may be propagated, studied or used for various purposes.
- the subject host may find a wide variety of uses by virtue of the significant presence of circulating human blood cells in the non-human host.
- the host may be employed for the production of human monoclonal antibodies or immortalized T lymphocytes.
- the host may be immunized in accordance with conventional ways with an appropriate immunogen, which may be injected intravascularly at an appropriate site. Of particular interest is injection at a site which is drained by a human lymph node introduced into the host.
- the immunized host may receive one or more booster shots, followed by removal of a lymphoid organ, e.g. lymph node, followed by immortalization, conveniently by fusion with an appropriate yeloid cell or transfection with Epstein-Barr virus.
- the cells may be cloned by any convenient means, at limiting dilution to provide for individual clones, and the supernatants of the individual clones may be screened for the binding affinity of the antibodies present in the host.
- the host may be used for studying T and B lymphocyte interactions, in determining the manner of stimulation of T and B lymphocytes and the mechanism for the immune reaction.
- Individual lymphocytes may be cloned to evaluate their role in disease protection against disease, identify slg or T cell receptor variable regions, isolate the DNA encoding the variable regions, or the like.
- Various immunogens may be screened for their abilities as vaccines in producing antibodies which may be effective in neutralizing pathogens and the cells or DNA provide a source of the variable regions associated with the response.
- Pathogens of interest are those particularly associated with humans, such as HIV, HTLV-I, and - II, human papilloma virus, cytomegalovirus, Epstein- Barr virus, hepatitis B virus, non-A, non-B hepatitis, chlamydia, malaria (Falciparum) etc.
- the subject system may be used in the study of cancer in attempting to develop cytotoxic cells specific for a particular cancer type.
- mice were transplanted into either untreated mice (6-10 weeks old) or mice (6-10 weeks old) pre-treated with radiation from a cesium 137 source.
- the mice are treated with either whole body irradiation or irradiation of the long bones.
- Mice treated with whole body irradiation receive 200 to 400 rads on a single dose.
- the mice are treated with 600 rads after shielding of the thorax and abdomen with a lead shield.
- the mice are anesthetized with Nembutol prior to shielded irradiation.
- the mice were CB-17.5 scid/scid mice.
- some of the mice were treated with exogenous human IL-3 in two l ⁇ g doses per day.
- the fetal bone pieces are prepared from fetuses of 18-22 week gestation by first removing all of the soft tissues and cartilagenous portions from the bone. The bones are then cross sectioned at 2 - 5 mm intervals. The mice are prepared by injection ip of Nembutol. Once the mice are fully anesthetized, a 1 cm incision is made in the skin as well as the underlying peritoneum. The bone fragments are then placed into the peritoneal cavity randomly. Approximately 25mm to 1.5cm of a femur, tibia or humerus is implanted into each mouse. The mice which are irradiated are irradiated within 24 hours of the subsequent implantation of the fetal bone.
- the percentage of human cells in the peripheral blood is determined by employing monoclonal antibodies specific for human hematopoietic cell markers.
- a low level of human cells is observed in the peripheral blood by FACScan.
- the positive cells vary from about 0 - 1.6 percent.
- injection of IL-3 does not significantly affect the percentage of positive cells.
- the mice irradiated before marrow transplantation showed between 1.5 and 30 percent human cells in the peripheral blood. These cells appear to be of the myelomonocytic lineage. They show no staining with T or B cell markers (CD 3, 4, 8, 19), although they do stain for the myeloid cell marker (CD33) .
- the human cells have a high side scatter profile indicating that they are of the myelomonocytic lineage.
- two of the four mice which were irradiated before implantation show low but significant levels of serum immunoglobulin after six weeks.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52921790A | 1990-05-25 | 1990-05-25 | |
US529,217 | 1990-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991018615A1 true WO1991018615A1 (en) | 1991-12-12 |
Family
ID=24108994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/003306 WO1991018615A1 (en) | 1990-05-25 | 1991-05-13 | Human peripheral blood cells in an immunocompromised host |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0484512A4 (en) |
JP (1) | JPH05500617A (en) |
CA (1) | CA2064075A1 (en) |
WO (1) | WO1991018615A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481058A1 (en) * | 1990-05-03 | 1992-04-22 | Systemix Inc | Human lymphoid tissue in an immunocompromised host. |
EP0539970A2 (en) * | 1991-10-30 | 1993-05-05 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
EP0625907A1 (en) * | 1991-11-22 | 1994-11-30 | Immunex Corporation | Chimeric mammals with human hematopoietic cells |
US5625128A (en) * | 1992-09-11 | 1997-04-29 | The Regents Of The University Of Michigan | Non-human animal model of a human airway |
US5652373A (en) * | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5804160A (en) * | 1991-06-04 | 1998-09-08 | Yeda Research And Development Co. Ltd | Animal model for hepatitis virus infection |
US5849987A (en) * | 1992-06-02 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5849288A (en) * | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
US5858328A (en) * | 1991-06-04 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5866757A (en) * | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US6060049A (en) * | 1993-05-24 | 2000-05-09 | Ximerex, Inc. | Surrogate tolerogenesis for the development of tolerance to xenografts |
US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
US9655352B2 (en) | 2011-02-15 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Humanized M-CSF mice |
US9820476B2 (en) | 2012-09-07 | 2017-11-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US9901082B2 (en) | 2012-11-05 | 2018-02-27 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US10123518B2 (en) | 2015-04-13 | 2018-11-13 | Regeneron Pharmaceuticals, Inc | Genetically modified non-human animals and methods of use thereof |
US10463028B2 (en) | 2014-05-19 | 2019-11-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human EPO |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0322240B1 (en) * | 1987-12-23 | 1995-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric immunocompromised mammals and their use |
JP2981486B2 (en) * | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | Mammalian immune system research methods |
-
1991
- 1991-05-13 WO PCT/US1991/003306 patent/WO1991018615A1/en not_active Application Discontinuation
- 1991-05-13 CA CA002064075A patent/CA2064075A1/en not_active Abandoned
- 1991-05-13 EP EP19910911224 patent/EP0484512A4/en not_active Withdrawn
- 1991-05-13 JP JP3510612A patent/JPH05500617A/en active Pending
Non-Patent Citations (9)
Title |
---|
Cancer Research, Volume 47, Issued 01 May 1987, REDDY et al., "Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency", pages 2456-2460, see the entire document. * |
Clin, Exp. Immunol., Volume 64, Issued 1986, POLMAR et al., "Long-term immunological reconstitution by peripheral blood leucocytes in severe combined immune deficiency disease: implications for the role of mature lymphocytes in histocompatible bone marrow transplantation", pages 518-525, see the entire document. * |
Journal of Immunological Methods, Volume 85, Issued 1985, WARE et al., "Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID)" pages 353-361, see the entire document. * |
Nat. Immun. Cell Growth Regul., Volume 4, Issued 1985, FOHLMEISTER et al., "The possibility of assaying Wistar rat bone marrow CFUs in a xenogeneic (rat-to-mouse) system", pages 221-228, see the entire document. * |
Nature, Volume 335, Issued 15 September 1988, MOSIER et al., "Transfer of a functional human immune systrem to mice with severe combined immunodeficiency", pages 256-259, see the entire document. * |
Science, Volume 241, Issued 23 September 1988, McCune, "The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function", pages 1632-1639, see the entire document. * |
See also references of EP0484512A4 * |
Tokai J. Exp. Clin. Med., Volume 10, Number 2, 3, Issued 1985, Pollard, "Protected environment and its utility in experimental allogeneic and xenogeneic bone marrow transplantation", pages 175-179, see the entire document. * |
Transplantation, Volume 44. Number 1, Issued 1987, WADE et al., "Characterization of xenogeneic mouse-to-rat bone marrow chimeras", pages 88-92, see the entire document. * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652373A (en) * | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5709843A (en) * | 1990-01-15 | 1998-01-20 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoietic deficient immune systems |
US5849288A (en) * | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
EP0481058A1 (en) * | 1990-05-03 | 1992-04-22 | Systemix Inc | Human lymphoid tissue in an immunocompromised host. |
EP0481058A4 (en) * | 1990-05-03 | 1993-07-14 | Systemix, Inc. | Human lymphoid tissue in an immunocompromised host |
US5804160A (en) * | 1991-06-04 | 1998-09-08 | Yeda Research And Development Co. Ltd | Animal model for hepatitis virus infection |
US5858328A (en) * | 1991-06-04 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5869268A (en) * | 1991-10-30 | 1999-02-09 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
US5681729A (en) * | 1991-10-30 | 1997-10-28 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
EP0539970A3 (en) * | 1991-10-30 | 1994-05-25 | Idemitsu Kosan Co | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
EP0539970A2 (en) * | 1991-10-30 | 1993-05-05 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
EP0625907A4 (en) * | 1991-11-22 | 1994-12-14 | Immunex Corporation | Chimeric mammals with human hematopoietic cells. |
EP0625907A1 (en) * | 1991-11-22 | 1994-11-30 | Immunex Corporation | Chimeric mammals with human hematopoietic cells |
US5849987A (en) * | 1992-06-02 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5866757A (en) * | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5667766A (en) * | 1992-09-11 | 1997-09-16 | The Regents Of The University Of Michigan | Non-human animal model of a human airway, methods of use |
US5625128A (en) * | 1992-09-11 | 1997-04-29 | The Regents Of The University Of Michigan | Non-human animal model of a human airway |
US6060049A (en) * | 1993-05-24 | 2000-05-09 | Ximerex, Inc. | Surrogate tolerogenesis for the development of tolerance to xenografts |
US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
US10278374B2 (en) | 2009-10-06 | 2019-05-07 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
US9301509B2 (en) | 2009-10-06 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
US9554563B2 (en) | 2009-10-06 | 2017-01-31 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
US8692052B2 (en) | 2009-10-06 | 2014-04-08 | Regeneron Pharmaceuticals | Genetically modified mice and engraftment |
US11051499B2 (en) | 2009-10-06 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
US9655352B2 (en) | 2011-02-15 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Humanized M-CSF mice |
US10785966B2 (en) | 2011-02-15 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | Humanized M-CSF mice |
US9820476B2 (en) | 2012-09-07 | 2017-11-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US10433527B2 (en) | 2012-09-07 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US11026408B2 (en) | 2012-09-07 | 2021-06-08 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US10785968B2 (en) | 2012-11-05 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US9986724B2 (en) | 2012-11-05 | 2018-06-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US9901082B2 (en) | 2012-11-05 | 2018-02-27 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US11778995B2 (en) | 2012-11-05 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US10463028B2 (en) | 2014-05-19 | 2019-11-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human EPO |
US11766032B2 (en) | 2014-05-19 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human EPO |
US10123518B2 (en) | 2015-04-13 | 2018-11-13 | Regeneron Pharmaceuticals, Inc | Genetically modified non-human animals and methods of use thereof |
US10561126B2 (en) | 2015-04-13 | 2020-02-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
US11576356B2 (en) | 2015-04-13 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2064075A1 (en) | 1991-11-26 |
EP0484512A4 (en) | 1993-05-05 |
EP0484512A1 (en) | 1992-05-13 |
JPH05500617A (en) | 1993-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991018615A1 (en) | Human peripheral blood cells in an immunocompromised host | |
Mueller et al. | Potential of the scid mouse as a host for human tumors | |
JP3753321B2 (en) | Method for producing mouse suitable for engraftment, differentiation and proliferation of heterologous cells, mouse produced by the method and use of the mouse | |
Naito et al. | Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice | |
DK2448967T3 (en) | NON-HUMAN MAMMALS MODEL OF CANCER human hematopoietic | |
Mosier | Immunodeficient mice xenografted with human lymphoid cells: new models for in vivo studies of human immunobiology and infectious diseases | |
WO2011002727A1 (en) | Methods of producing humanized non-human mammals | |
CN104918483A (en) | Genetically modified non-human animals and methods of use thereof | |
JPH0213336A (en) | Transfer of functional human immune system to mouse of severe combined immunodeficiency | |
Salomon et al. | Conditional ablation of dendritic cells in transgenic mice. | |
Murphy et al. | Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein Barr virus-induced B-cell lymphoma | |
JP4906059B2 (en) | Screening method for human platelet number regulator | |
US6455756B1 (en) | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice | |
US5434341A (en) | Xenogeneic lymph node in mammary fat pad | |
GRÖNVIK et al. | Monoclonal Antibodies against Murine Neonatal and Pregnancy‐Associated Natural Suppressor Cells Induce Resorption of the Fetus | |
Leblond et al. | The SCID mouse mutant: definition and potential use as a model for immune and hematological disorders | |
Tyan | Thymus: role in maturation of fetal lymphoid precursors | |
Eswaraka et al. | Humanized mice and PDX models | |
US7259290B1 (en) | Animal model of human hematopoietic tumor | |
Song et al. | Functional analysis of human hematopoietic stem cells in vivo in humanized mice | |
Camacho et al. | Characterization of the NOD/scid-[Tg] DR1 mouse expressing HLA-DRB1∗ 01 transgene: a model of SCID-hu mouse for vaccine development | |
Boniver et al. | Target cells and thymus microenvironment in the pathogenesis of thymic lymphomas in C57BL/Ka mice | |
WO2009105244A1 (en) | Recombiant non-human mammalian model for hepatitis infection and immunopathogenesis | |
Bubbers | Single-gene abrogation of spontaneous pleomorphic SJL/J mouse reticulum cell sarcoma expression | |
Wagner et al. | c-fos and polyoma middle T oncogene expression in transgenic mice and embryonal stem cell chimaeras |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2064075 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991911224 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991911224 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991911224 Country of ref document: EP |